Get In Touch

Global Monoclonal Antibody Therapeutics Market: Snapshot

The biological therapy used for treating various kinds of severe and chronic conditions are known as monoclonal antibodies. These are applied in the treatment of serious conditions such as cancer, rheumatoid arthritis, Crohn’s diseases, psoriasis, osteoporosis, systemic lupus erythematous and others. These are target only the affected areas to destroy the diseased cells, thus restoring the immune system. The research report by Transparency Market Research states that the global monoclonal antibody therapeutics market was worth US$86.7 bn in 2015 and is expected to reach US$245.8 bn by 2024. Between the forecast years of 2016 and 2024, the overall market is expected to rise at a CAGR of 12.6%.

The rising incidence of cancer across the globe is expected to drive the global market in the coming years. According to the World Health Organization, the world is expected to witness a rise of 70% in the number of cancer cases over the next few years. The statistics indicate that of these, 60% will be from Asia, Africa, and Latin America. The market is also likely to be favored by the growing approvals to research and develop new antibodies, especially across Europe and the U.S. Additionally, commercialization of these drugs will also contribute to the growing revenue of the global market.

monoclonal antibody therapeutics market

Autoimmune Diseases Showcase Steady Demand for Monoclonal Antibody Therapeutics

On the basis of application, the global monoclonal antibody therapeutics market is segmented into cancer, ophthalmological diseases, infection, autoimmune diseases, and hematological diseases among others. Of these, demand for treating autoimmune diseases with monoclonal antibody therapeutics is expected to remain at an all-time high in the coming years. The growing awareness about diseases, improving accessibility to healthcare, widening range of monoclonal antibody therapeutics, and huge investments in research and development of these therapeutics are expected to propel the segment in the coming years. Cancer is the second largest segment in the global market due to the high prevalence of the disease and an urgent need to treat the same.

North America to Remain Leading Segment due to Affordable Healthcare

In terms of geography, the global market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Analysts predict that the North America monoclonal antibody therapeutics market is likely to lead due to several reasons. Europe is expected to follow suit. As of 2015, the collective share of these two regions stood at 62.7% in the global market. The vast pool of geriatrics, well-established reimbursement policies, affordable healthcare, and growing awareness of diseases is expected to drive the market in North America in the coming few years. On the other hand, Europe monoclonal antibody therapeutics market is expected to thrive due to the increasing research and development in developing novel products.

Asia Pacific is also expected to show promise of a steady growth as the region has a huge population base with vast scope of unmet medical needs. The growing focus of governments in developing countries to improve the healthcare facilities is also expected to boost the demand for monoclonal antibody therapeutics in the coming years.

The key players operating in the global monoclonal antibody therapeutics market are GlaxoSmithKline Plc., Bayer AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., Sanofi, Merck & Co., Inc., AbbVie Inc., Novartis AG, Amgen Inc., Bristol – Myers Squibb Company, Johnson & Johnson, and Biogen Inc. among others.  The players are expected to focus on strategic mergers and acquisitions in the coming years to improve their foothold in the global market.

Monoclonal Antibody (mAb) Therapeutics Market Witnesses Massive Growth Potential in Demand for Drugs for Human Diseases

The pipeline of drugs in therapeutic antibodies has continuously grown in revenue potential. Over the past 25 years, therapeutic antibody drugs have opened new vistas in humanization of monoclonal antibodies (mAb), notably in the treatment of numerous cancer types, autoimmune disorders, and infectious diseases. A number of approvals of mAb by the U.S. FDA over the past three decades is a key trend from which has stemmed massive swatches of research investments by pharmaceutical companies in the monoclonal antibody (mAb) therapeutics market. Strides in the therapeutic antibody drugs pivot on advancements in purification technologies. A number of them are being investigated in clinical trials around the world, which is a key trend propelling the valuation growth in the monoclonal antibody (mAb) therapeutics market. One such technique is complementary-determining region (CDR) grafting, highly production in the development of humanized antibodies. Growing demand for biologics for autoimmune diseases and conditions that need prolonged treatment has been expanding the canvas for approval of therapeutic mAbs. The growing approval of human antibody drugs in recent years underscores the significant growth potential of the monoclonal antibody (mAb) therapeutics market.

Medical researchers are relentlessly pursuing the objectives of increasing the safety and efficacy of the existing therapeutic antibodies. Thus, pharmaceutical companies developing antibody-based drugs have made therapeutic breakthroughs. Continuing efforts complemented by technological advancements will likely pave way to improved classes of drugs in several diseases. These include asthma, Crohn’s disease, arthritis, transplant rejection, and migraine headaches. In particular, new platforms for developing bispecific antibodies are likely to bring new avenues in infectious diseases. In the current scenario of severe acute respiratory syndrome coronavirus 2, named as COVID-19, there is a pressing need for emergency authorization of monoclonal antibody (mAb) therapeutics. These hold promise in lowering the viral load and the severity of hospitalization. A large part of public resources are aimed at boosting the necessary medical infrastructure, and mAb, shows new paths of reducing the disease severity. 

Global Monoclonal Antibody Therapeutics Market: Overview

Monoclonal antibodies are a type of biological therapy used in the treatment serious conditions such as cancer, rheumatoid arthritis, Crohn’s diseases, psoriasis, osteoporosis, systemic lupus erythematous, and others. Monoclonal antibody are target specific in action by not affect the other cells of the body thus restores the immune system.

The market report comprises an elaborated executive summary, which includes market snapshot that provides information about various segments of the market. It also provides information and data analysis of the market with respect to market segments based on application, source, end-user, and geography. The market overview section of the report analyzes market dynamics such as drivers, restraints and opportunities that influences the market in the current and future scenario.

Global Monoclonal Antibody Therapeutics Market: Segmentation

This report analyzes the current and future prospects of the market based on type of application, source, end user and geography. By application monoclonal antibodies are segmented according to the therapeutic area such as cancer, autoimmune diseases, infection, hematological diseases, ophthalmological diseases and others which include monoclonal antibodies used in treating cardiovascular, respiratory, and orthopedic disorders as well as monoclonal antibodies used in the prevention of transplant rejection.

By source monoclonal antibodies are segmented into human, humanized, chimeric, and others, which include peptide body and murine antibodies. The human monoclonal antibody segment is expected to be highest contributing segment in the monoclonal antibody therapeutic market during the forecast period. Various factors such as patent expiry of block buster drugs, robust pipeline of monoclonal antibodies indicated in the treating various types of cancer and other disorders such as hematological, cardiovascular and orthopedic and upcoming biosimilars, define the market growth over the forecast period.

Global Monoclonal Antibody Therapeutics Market: Research Methodology

The research is a combination of primary and secondary research, conducted for understanding and arriving at trends, used to forecast the expected revenue of the major market in the near future. Primary research formed the bulk of our research efforts with information collected from in-depth interviews and discussions with a number of key industry experts and opinion leaders. Secondary research involved study of company websites, annual reports, press releases, investor presentations, analyst presentation and various international and national databases.

The report provides estimated market size in terms of US$ Mn for each by application, source, end user, and geography for the period 2014 to 2024, considering the macro and micro environmental factors. The revenue generated from each product was calculated by considering number of products used in the procedures and their market demand as per their use, number of product launched, annual revenue generated by products of each sub segment, trends in industry, end user trend, and adoption rate across all the geographies.

Global Monoclonal Antibody Therapeutics Market: Regional Outlook

Market share analysis among the market players is analyzed to signify the contribution of these players in the market in terms of percentage share. All these factors will help the market players to decide about the business strategies and plans to strengthen their positions in the global market. Based on geography, the market has been analyzed for major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The study also covers detailed country analysis contributing majorly in the market.

Key Players Mentioned in this Report are:

The report also profiles the major players in the market and provides various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major companies profiled in the monoclonal antibody therapeutics market are Bayer AG, F. Hoffmann-La Roche Ltd., Pfizer Inc., Sanofi, GlaxoSmithKline Plc., Merck & Co., Inc., Novartis AG, AbbVie Inc., Amgen Inc., Johnson & Johnson, Bristol – Myers Squibb Company and  Biogen Inc.   .

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

The monoclonal antibody therapeutics market has been segmented as follows:

By Application

  • Cancer
  • Autoimmune diseases
  • Infection
  • Hematological diseases
  • Ophthalmological diseases
  • Others

By Source

  • Human
  • Humanized
  • Chimeric
  • Others

By End Users

  • Hospitals
  • Private Clinics
  • Research Institute

By Geography

  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Europe
    • U.K.
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • India
    • Japan
    • China
    • Australia
    • New Zealand
    • Rest of Asia Pacific
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • A.E.
    • Rest of MEA

With a robust experience in creating exceptional market reports, Transparency Market Research has emerged as one of the trusted market research companies among a large number of stakeholders and CXOs. Every report at Transparency Market Research goes through rigorous research activity in every aspect. The researchers at TMR keep a close watch on the market and extract beneficial growth-boosting points. These points help the stakeholders to strategize their business plans accordingly.

TMR researchers conduct exhaustive qualitative and quantitative research. This research involves taking inputs from the experts in the market, focused attention on recent developments, and others. This method of research makes TMR stand out from other market research firms.

Here's how Transparency Market Research helps the stakeholders and CXOs through the reports:

Inculcation and Evaluation of Strategic Collaborations: The TMR researchers analyze recent strategic activities like mergers, acquisitions, partnerships, collaborations, and joint ventures. All the information is compiled and included in the report.

Perfect Market Size Estimations: The report analyzes the demographics, growth potential, and capability of the market through the forecast period. This factor leads to the estimation of the market size and also provides an outline about how the market will retrieve growth during the assessment period.

Investment Research: The report focuses on the ongoing and upcoming investment opportunities across a particular market. These developments make the stakeholders aware of the current investment scenario across the market.

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Monoclonal Antibody Therapeutics Market 

4. Market Overview
     4.1. Introduction
            4.1.1. Application Definition
            4.1.2. Industry Evolution / Developments
     4.2.  Overview
     4.3. Key Market Indicators
            4.3.1. Region/Country Specific
            4.3.2. Product/Application/End Users Specific
            4.3.3. Target Market Specific – Global Scenario
     4.4. Market Dynamics
            4.4.1. Drivers
            4.4.2. Restraints
            4.4.3. Opportunity
     4.5. Global Monoclonal Antibody Therapeutics Market  Analysis and Forecasts, 2014–2024
            4.5.1. Market Revenue Projections (US$ Mn)
     4.6. Monoclonal Antibody Therapeutics Market  - Global Supply Demand Scenario
     4.7. Porter’s Five Force Analysis
     4.8. Value Chain Analysis
     4.9. Market Outlook

5. Global Monoclonal Antibody Therapeutics Market  Analysis and Forecasts, By Application 
     5.1. Introduction & Definition
     5.2. Key Findings / Developments
     5.3. Key Trends
     5.4. Market Value  Forecast By Application , 2014–2024
            5.4.1. Cancer 
            5.4.2. Autoimmune diseases 
            5.4.3. Infection 
            5.4.4. Hematological diseases 
            5.4.5. Ophthalmological diseases 
            5.4.6. Others
     5.5. Market Attractiveness By Application 

6. Global Monoclonal Antibody Therapeutics Market  Analysis and Forecasts, By Source 
     6.1. Introduction & Definition
     6.2. Key Findings / Developments
     6.3. Key Trends
     6.4. Market Value  Forecast By Source , 2014–2024
            6.4.1. Human 
            6.4.2. Humanized 
            6.4.3. Chimeric 
            6.4.4. Others 
     6.5. Market Attractiveness By Source 

7. Global Monoclonal Antibody Therapeutics Market  Analysis and Forecasts, By End Users 
     7.1. Introduction & Definition
     7.2. Key Findings / Developments
     7.3. Key Trends
     7.4. Market Value  Forecast By End Users , 2014–2024
            7.4.1. Hospital
            7.4.2. Private Clinic 
            7.4.3. Research Institutes 
     7.5. Market Attractiveness By End Users 

8. Global Monoclonal Antibody Therapeutics Market  Analysis and Forecasts, By Region
     8.1. Key Findings
     8.2. Policies and Regulations
     8.3. Market Value  Forecast By Region
            8.3.1. North America 
            8.3.2. Europe 
            8.3.3. Asia Pacific 
            8.3.4. Latin America  
            8.3.5. Middle East & Africa 
     8.4. Market Attractiveness By Country/Region

9. North America Monoclonal Antibody Therapeutics Market  Analysis and Forecast
     9.1. Introduction
            9.1.1. Key Findings
            9.1.2. Key Trends
     9.2. Market Value  Forecast By Application , 2014–2024
            9.2.1. Cancer 
            9.2.2. Autoimmune diseases 
            9.2.3. Infection 
            9.2.4. Hematological diseases 
            9.2.5. Ophthalmological diseases 
            9.2.6. Others
     9.3. Market Value  Forecast By Source , 2014–2024
            9.3.1. Human 
            9.3.2. Humanized 
            9.3.3. Chimeric 
            9.3.4. Others 
     9.4. Market Value  Forecast By End Users , 2014–2024
            9.4.1. Hospital
            9.4.2. Private Clinic 
            9.4.3. Research Institutes 
     9.5. Market Value  Forecast By Country , 2014–2024
            9.5.1. U.S.
            9.5.2. Canada
     9.6. Market Attractiveness Analysis 
            9.6.1. By Application 
            9.6.2. By Source 
            9.6.3. By End Users 
            9.6.4. By Country

10. Europe Monoclonal Antibody Therapeutics Market  Analysis and Forecast
     10.1.Introduction
            10.1.1. Key Findings
            10.1.4. Key Trends
     10.2.Market Value  Forecast By Application , 2014–2024
            10.2.1. Cancer 
            10.2.2. Autoimmune diseases 
            10.2.3. Infection 
            10.2.4. Hematological diseases 
            10.2.5. Ophthalmological diseases 
            10.2.6. Others
     10.3.Market Value  Forecast By Source , 2014–2024
            10.3.1. Human 
            10.3.2. Humanized 
            10.3.3. Chimeric 
            10.3.4. Others 
     10.4.Market Value  Forecast By End Users , 2014–2024
            10.4.1. Hospital
            10.4.2. Private Clinic 
            10.4.3. Research Institutes 
     10.5.Market Value  Forecast By Country , 2014–2024
            10.5.1. Germany
            10.5.2. U.K.
            10.5.3. France
            10.5.4. Spain
            10.5.5. Italy
            10.5.6. Rest of Europe 
     10.6.Market Attractiveness Analysis 
            10.6.1. By Application 
            10.6.2. By Source 
            10.6.3. By End Users 
            10.6.4. By Country

11. Asia Pacific Monoclonal Antibody Therapeutics Market  Analysis and Forecast
     11.1.Introduction
            11.1.1. Key Findings
            11.1.4. Key Trends
     11.2.Market Value  Forecast By Application , 2014–2024
            11.2.1. Cancer 
            11.2.2. Autoimmune diseases 
            11.2.3. Infection 
            11.2.4. Hematological diseases 
            11.2.5. Ophthalmological diseases 
            11.2.6. Others
     11.3.Market Value  Forecast By Source , 2014–2024
            11.3.1. Human 
            11.3.2. Humanized 
            11.3.3. Chimeric 
            11.3.4. Others 
     11.4.Market Value  Forecast By End Users , 2014–2024
            11.4.1. Hospital
            11.4.2. Private Clinic 
            11.4.3. Research Institutes 
     11.5.Market Value  Forecast By Country , 2014–2024
            11.5.1. Japan
            11.5.2. China
            11.5.3. Australia
            11.5.4. New Zealand
            11.5.5. India
            11.5.6. Rest of Asia Pacific
     11.6.Market Attractiveness Analysis 
            11.6.1. By Application 
            11.6.2. By Source 
            11.6.3. By End Users 
            11.6.4. By Country

12. Latin America  Monoclonal Antibody Therapeutics Market  Analysis and Forecast
     12.1.Introduction
            12.1.1. Key Findings
            12.1.4. Key Trends
     12.2.Market Value  Forecast By Application , 2014–2024
            12.2.1. Cancer 
            12.2.2. Autoimmune diseases 
            12.2.3. Infection 
            12.2.4. Hematological diseases 
            12.2.5. Ophthalmological diseases 
            12.2.6. Others
     12.3.Market Value  Forecast By Source , 2014–2024
            12.3.1. Human 
            12.3.2. Humanized 
            12.3.3. Chimeric 
            12.3.4. Others 
     12.4.Market Value  Forecast By End Users , 2014–2024
            12.4.1. Hospital
            12.4.2. Private Clinic 
            12.4.3. Research Institutes 
     12.5.Market Value  Forecast By Country , 2014–2024
            12.5.1. Brazil
            12.5.2. Mexico
            12.5.3. Rest of Latin America 
     12.6.Market Attractiveness Analysis 
            12.6.1. By Application 
            12.6.2. By Source 
            12.6.3. By End Users 
            12.6.4. By Country

13. Middle East & Africa Monoclonal Antibody Therapeutics Market  Analysis and Forecast
     13.1.Introduction
            13.1.1. Key Findings
            13.1.4. Key Trends
     13.2.Market Value  Forecast By Application , 2014–2024
            13.2.1. Cancer 
            13.2.2. Autoimmune diseases 
            13.2.3. Infection 
            13.2.4. Hematological diseases 
            13.2.5. Ophthalmological diseases 
            13.2.6. Others
     13.3.Market Value  Forecast By Source , 2014–2024
            13.3.1. Human 
            13.3.2. Humanized 
            13.3.3. Chimeric 
            13.3.4. Others 
     13.4.Market Value  Forecast By End Users , 2014–2024
            13.4.1. Hospital
            13.4.2. Private Clinic 
            13.4.3. Research Institutes 
     13.5.Market Value  Forecast By Country , 2014–2024
            13.5.1. South Africa
            13.5.2. UAE
            13.5.3. Saudi Arabia
            13.5.4. Rest of Middle East and Africa 
     13.6.Market Attractiveness Analysis 
            13.6.1. By Application 
            13.6.2. By Source 
            13.6.3. By End Users 
            13.6.4. By Country

14. Competition Landscape
     14.1.Market Player – Competition Matrix (By Tier and Size of companies)
     14.2.Market Share Analysis By Company (2015)
     14.3.Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
            14.3.1. Bayer AG
                      14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                      14.3.1.2. Financial Overview
                      14.3.1.3. Product Portfolio
                      14.3.1.4. SWOT Analysis 
                      14.3.1.5. Strategic Overview
            14.3.2. F. Hoffmann-La Roche Ltd. 
                      14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                      14.3.2.2. Financial Overview
                      14.3.2.3. Product Portfolio
                      14.3.2.4. SWOT Analysis 
                      14.3.2.5. Strategic Overview
            14.3.3. Pfizer, Inc. 
                      14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                      14.3.3.2. Financial Overview
                      14.3.3.3. Product Portfolio
                      14.3.3.4. SWOT Analysis 
                      14.3.3.5. Strategic Overview
            14.3.4. Sanofi
                      14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                      14.3.4.2. Financial Overview
                      14.3.4.3. Product Portfolio
                      14.3.4.4. SWOT Analysis 
                      14.3.4.5. Strategic Overview
            14.3.5. GlaxoSmithKline plc.
                      14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                      14.3.5.2. Financial Overview
                      14.3.5.3. Product Portfolio
                      14.3.5.4. SWOT Analysis 
                      14.3.5.5. Strategic Overview 
            14.3.6. Merck & Co., Inc. 
                      14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                      14.3.6.2. Financial Overview
                      14.3.6.3. Product Portfolio
                      14.3.6.4. SWOT Analysis 
                      14.3.6.5. Strategic Overview
            14.3.7. Novartis AG 
                      14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                      14.3.7.2. Financial Overview
                      14.3.7.3. Product Portfolio
                      14.3.7.4. SWOT Analysis 
                      14.3.7.5. Strategic Overview
            14.3.8. AbbVie Inc. 
                      14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                      14.3.8.2. Financial Overview
                      14.3.8.3. Product Portfolio
                      14.3.8.4. SWOT Analysis 
                      14.3.8.5. Strategic Overview
            14.3.9. Amgen Inc. 
                      14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                      14.3.9.2. Financial Overview
                      14.3.9.3. Product Portfolio
                      14.3.9.4. SWOT Analysis 
                      14.3.9.5. Strategic Overview
            14.3.10. Johnson & Johnson
                      14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
                      14.3.10.2. Financial Overview
                      14.3.10.3. Product Portfolio
                      14.3.10.4. SWOT Analysis 
                      14.3.10.5. Strategic Overview 
            14.3.11. Bristol-Myers Squibb Company 
                      14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
                      14.3.11.2. Financial Overview
                      14.3.11.3. Product Portfolio
                      14.3.11.4. SWOT Analysis 
                      14.3.11.5. Strategic Overview
            14.3.12. Biogen Inc. 
                      14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
                      14.3.12.2. Financial Overview
                      14.3.12.3. Product Portfolio
                      14.3.12.4. SWOT Analysis 
                      14.3.12.5. Strategic Overview

List of Tables

Table 01: Global Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Application, 2014–2024
Table 02: Global Market Size (US$ Mn) Forecast, by Source, 2014–2024
Table 03: Global Market Size (US$ Mn) Forecast, by End Users, 2014–2024
Table 04: Global Market Size (US$ Mn) Forecast, by Region, 2014–2024
Table 05: North America Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Application, 2014–2024
Table 06: North America Market Size (US$ Mn) Forecast, by Source, 2014–2024
Table 07: North America Market Forecast, by End Users, 2014–2024
Table 08: North America Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 09: Europe Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Application, 2014–2024
Table 10: Europe Market Size (US$ Mn) Forecast, by Source, 2014–2024
Table 11: Europe Monoclonal Antibody Therapeutics Market Forecast, by End Users, 2014–2024
Table 12: Europe Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 13: Asia Pacific Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Application, 2014–2024
Table 14: Asia Pacific Market Size (US$ Mn) Forecast, by Source, 2014–2024
Table 15: Asia Pacific Monoclonal Antibody Therapeutics Market Forecast, by End Users, 2014–2024
Table 16: Asia Pacific Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 17: Latin America Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Application, 2014–2024
Table 18: Latin America Market Size (US$ Mn) Forecast, by Source, 2014–2024
Table 19: Latin America Market Forecast, by End Users, 2014–2024
Table 20: Latin America Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 21: MEA Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Application, 2014–2024
Table 22: MEA Market Size (US$ Mn) Forecast, by Source, 2014–2024
Table 23: MEA Market Forecast, by End Users, 2014–2024
Table 24: MEA Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Country, 2014–2024

List of Figures

Figure  1: Market Value Share By Application (2016) Revenue (US$ Mn)
Figure  2: Market Value Share By Source(2016) Revenue (US$ Mn)
Figure  3: Market Value Share By Application & Source (2016) Revenue (US$ Mn)
Figure  3: Market Value Share By End Users  (2016) Revenue (US$ Mn)
Figure  4: Market Value Share By Region (2016) Revenue (US$ Mn)
Figure  3: Market Value Share By End Users & Region (2016) Revenue (US$ Mn)
Figure  5: Global Monoclonal Antibody Therapeutics Market Value Share Analysis, by Application, 2015 and 2024
Figure  6: Global Cancer  Market Revenue (US$ Mn), 2014–2024
Figure  7: Global Autoimmune diseases Market Revenue (US$ Mn), 2014–2024
Figure  8: Global Infection Market Revenue (US$ Mn), 2014–2024
Figure  9: Global Hematological diseases  Market Revenue (US$ Mn), 2014–2024
Figure  10: Global Ophthalmic diseases Market Revenue (US$ Mn), 2014–2024
Figure  11: Global Others Market Revenue (US$ Mn), 2014–2024
Figure  12: Global Monoclonal Antibody Therapeutics Market Attractiveness Analysis By Application, 2015
Figure  13: Global Monoclonal Antibody Therapeutics Market Value Share Analysis, by Source, 2015 and 2024
Figure  14: Global Human Market Revenue (US$ Mn), 2014–2024
Figure  15: Global Humanized Market Revenue (US$ Mn), 2014–2024
Figure  16: Global Chimeric Market Revenue (US$ Mn), 2014–2024
Figure  17: Global Others Market Revenue (US$ Mn), 2014–2024
Figure  18: Global Monoclonal Antibody Therapeutics Market Attractiveness Analysis By Source, 2015
Figure  19: Global Monoclonal Antibody Therapeutics Market Value Share Analysis, by End Users, 2015 and 2024
Figure  20: Global Hospital Market Revenue (US$ Mn), 2014–2024
Figure  21: Global Private Clinics Market Revenue (US$ Mn), 2014–2024
Figure  22: Global Research Institutes  Market Revenue (US$ Mn), 2014–2024
Figure  23: Global Monoclonal Antibody Therapeutics Market Attractiveness Analysis By End Users, 2015
Figure  24: Global Monoclonal Antibody Therapeutics Market Value Share Analysis, by Region, 2015 and 2024
Figure  25: Global Monoclonal Antibody Therapeutics Market Attractiveness Analysis By Region, 2015
Figure  26: North America Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, 2015–2024
Figure  27: North America Monoclonal Antibody Y-o-Y Growth Projections, 2015–2024
Figure  28: North America Monoclonal Antibody Therapeutics  Market Attractiveness By Country, 2014–2024
Figure  29: North America Market Value Share Analysis, by Application, 2015 and 2024
Figure  30: North America Market Value Share Analysis, by Source, 2015 and 2024
Figure  31: North America Market Value Share Analysis, by End Users, 2015 and 2024
Figure  32: North America Market by Country, 2015 and 2024
Figure  33: North America Monoclonal Antibody Therapeutics Market Attractiveness Analysis, by Application, 2015
Figure  34: North America Market Attractiveness Analysis, by Source, 2015
Figure  35: North America Market Attractiveness Analysis, By End users, 2015
Figure  36 : Europe Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, 2015–2024
Figure  37: Europe Monoclonal Antibody Y-o-Y Growth Projections, 2015–2024
Figure  38: Europe  Market Attractiveness By Country, 2014–2024
Figure  39: Europe Market Value Share Analysis, by Application, 2015 and 2024
Figure  40 : Europe Monoclonal Antibody Therapeutics Market Value Share Analysis, by Source, 2015 and 2024
Figure  41: Europe Market Value Share Analysis, by End Users, 2015 and 2024
Figure  42: Europe Monoclonal Antibody Therapeutics Market by Country, 2015 and 2024
Figure  43: Europe Market Attractiveness Analysis, by Application, 2015
Figure  44: Europe Market Attractiveness Analysis, by Source, 2015
Figure  45: Europe Market Attractiveness Analysis, by End Users, 2015
Figure  46: Asia Pacific Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, 2015–2024
Figure  47: Asia Pacific Monoclonal Antibody Y-o-Y Growth Projections, 2015–2024
Figure  48: Asia Pacific Market Attractiveness By Country, 2014–2024
Figure  49: Asia Pacific Monoclonal Antibody Therapeutics Market Value Share Analysis, by Application, 2015 and 2024
Figure  50: Asia Pacific Market Value Share Analysis, by Source, 2015 and 2024
Figure  51: Asia Pacific Monoclonal Antibody Therapeutics Market Value Share Analysis, by End Users, 2015 and 2024
Figure  52: Asia Pacific Market by Country, 2015 and 2024
Figure  53: Asia Pacific Monoclonal Antibody Therapeutics Market Attractiveness Analysis, by Application, 2015
Figure  54: Asia Pacific Market Attractiveness Analysis, by Source, 2015
Figure  55: Asia Pacific Monoclonal Antibody Therapeutics Market Attractiveness Analysis, by End Users, 2015
Figure  56: Latin America Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, 2015–2024
Figure  57: Latin America Monoclonal Antibody Y-o-Y Growth Projections, 2015–2024
Figure  58: Latin America Monoclonal Antibody Therapeutics  Market Attractiveness By Country, 2014–2024
Figure  59: Latin America Market Value Share Analysis, by Application, 2015 and 2024
Figure  60: Latin America Monoclonal Antibody Therapeutics Market Value Share Analysis, by Source, 2015 and 2024
Figure  61: Latin America Market Value Share Analysis, by End Users, 2015 and 2024
Figure  62: Latin America Monoclonal Antibody Therapeutics Market by Country, 2015 and 2024
Figure  63: Latin America Market Attractiveness Analysis, by Application, 2015
Figure  64: Latin America Monoclonal Antibody Therapeutics Market Attractiveness Analysis, by Source, 2015
Figure  65: Latin America Market Attractiveness Analysis, by End Users, 2015
Figure  66: MEA Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, 2015–2024
Figure  67: MEA Monoclonal Antibody Y-o-Y Growth Projections, 2015–2024
Figure  68: MEA Monoclonal Antibody Therapeutics  Market Attractiveness By Country, 2014–2024
Figure  69: MEA Market Value Share Analysis, by Application, 2015 and 2024
Figure  70: MEA Monoclonal Antibody Therapeutics Market Value Share Analysis, by Source, 2015 and 2024
Figure  71: MEA Market Value Share Analysis, by End Users, 2015 and 2024
Figure  72: MEA Monoclonal Antibody Therapeutics Market by Country, 2015 and 2024
Figure  73: MEA Monoclonal Antibody Therapeutics Market Attractiveness Analysis, by Application, 2015
Figure  74: MEA Monoclonal Antibody Therapeutics Market Attractiveness Analysis, by Source, 2015
Figure  75: MEA Monoclonal Antibody Therapeutics Market Attractiveness Analysis, by End Users, 2015
Figure  76: Global Monoclonal Antibody Therapeutics Market Share Analysis, by Company (2015)

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Monoclonal Antibody Therapeutics Market